Quick Answer
Autolus Therapeutics plc reported Net Income Loss of -$287.53 million for the year ending 2025.
- Autolus Therapeutics plc showed a decrease of -30.3% in Net Income Loss from 2024 to 2025.
- This data is from Autolus Therapeutics plc's annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Autolus Therapeutics plc's Net Income Loss has declined by 2,191.1%.
- Historical annual values: Fiscal year 2025: -$287.53 million | Fiscal year 2024: -$220.66 million | Fiscal year 2023: -$208.38 million | Fiscal year 2022: -$148.84 million | Fiscal year 2021: -$142.10 million | Fiscal year 2020: -$142.09 million | Fiscal year 2019: -$123.85 million | Fiscal year 2018: -$44.75 million | Fiscal year 2017: -$19.73 million | Fiscal year 2016: -$12.55 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: